COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ITR
|
|||
| Drug Name |
PMID26868298-compound-N3
|
|||
| Synonyms |
PMID26868298-C-N3
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) | Investigative | [1] | Middle East Respiratory Syndrome (MERS) | Preclinical | [2] | Severe acute respiratory syndrome (SARS) | Preclinical | [2] |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | COVID-19 papain-like proteinase (PL-PRO) | Target Info | Inhibitor | [1] |
| Compound N3 inhibits SARS-CoV-2 Mpro through a combination of structure-based virtual and high-throughput screening experiment. | ||||
| MERS-CoV 3C-like proteinase (3CLpro) | Target Info | Inhibitor | [2] | |
| Compound N3, a 3CLpro inhibitor, demonstrates broad-spectrum in vitro activities against SARS-CoV and MERS-CoV with highly similar key residues for substrate recognition at their 3CLpro enzymes. | ||||
| SARS-CoV 3C-like protease (3CLpro) | Target Info | Inhibitor | [2] | |
| Compound N3, a 3CLpro inhibitor, demonstrates broad-spectrum in vitro activities against SARS-CoV and MERS-CoV with highly similar key residues for substrate recognition at their 3CLpro enzymes. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. | |||
| 2 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.